在童颜针代理权之争陷入"拉锯战"背后，江苏吴中已经退市，爱美客的业绩也难言乐观。 与爱美客争夺"童颜针"代理权的江苏吴中，退市后又有了新动作。 据江苏吴中医药发展股份有限公司（以下简称"江苏吴中"）近日发布的公告，公司拟以8000万元将其持有的全资 孙公司吴中美学生物科技（上海）有限公司（以下简称"上海吴中美学"）100%股权进行对外转让，受让方为上海 青愈生物科技有限公司（以下简称"上海青愈生物"）。 8000万元转让孙公司，退市后江苏吴中"断臂求生" 江苏吴中拟8000万元转让孙公司，主要原因之一便是"还债"。 在公告中，江苏吴中坦言，当前面临现金流短缺压力，且部分存量债务即将到期。转让上海吴中美学100%股权， 可以"优化公司资产结构，盘活存量资产，并切实解决债务问题。" 从标的公司来看，上海吴中美学主要业务为医美产品的研发生产，是江苏吴中医美生科板块旗下的公司。审计报 告显示，截至2025年11月30日，上海吴中美学经审计的资产总额约1.04亿元，所有者权益约7308.92万元。 童颜针代理权之争陷入"拉锯战"，临时措施被取消 此次转让上海吴中美学100%股权，或是江苏吴中收缩医美板块的缩影。 回顾江 ...

格隆汇2月24日丨敷尔佳(301371.SZ)公布，近日，公司在研产品"重组Ⅲ型人源化胶原蛋白冻干纤维"已 完成临床试验并取得临床试验总结报告，可以进行注册申报材料递交。"重组Ⅲ型人源化胶原蛋白冻干 纤维"为公司首款浅层注射填充类产品，本次该产品完成临床试验并取得临床试验总结报告，标志着公 司已经可以进行注册申报材料递交，对公司开拓医美院线市场、丰富产品线具有重要意义。 ...

格隆汇2月24日丨敷尔佳(301371.SZ)公布，近日，公司在研产品"重组Ⅲ型人源化胶原蛋白冻干纤维"已 完成临床试验并取得临床试验总结报告，可以进行注册申报材料递交。"重组Ⅲ型人源化胶原蛋白冻干 纤维"为公司首款浅层注射填充类产品，本次该产品完成临床试验并取得临床试验总结报告，标志着公 司已经可以进行注册申报材料递交，对公司开拓医美院线市场、丰富产品线具有重要意义。 ...

Recent Events - The arbitration case between the company's subsidiary REGEN and Datoo regarding the agency rights for the AestheFill product is still under review. On January 30, 2026, the Shenzhen International Arbitration Court revoked the previous temporary sales restriction on REGEN, but the final outcome of the case has not yet been announced, which may impact the company's future business layout [2]. Business Development - The company is accelerating its diversification efforts, with the anti-hair loss product Minoxidil having obtained a drug registration certificate and is advancing in market promotion. The bone structure beauty filler product "Gekela" has received positive market feedback. These new products may become future growth points, although specific sales targets have not been publicly disclosed [3]. Financial Performance - In the first three quarters of 2025, the company reported revenue of 1.865 billion yuan and a net profit attributable to shareholders of 1.093 billion yuan, representing year-on-year declines of 21.49% and 31.05%, respectively. The gross profit margin remains high at 93.36%. The ongoing pressure on performance is attributed to intensified industry competition [4]. Stock and Capital Performance - Recent stock price fluctuations have been significant, with two large block trades occurring on February 3, 2026, at a transaction price of 113 yuan per share, reflecting a discount of 23.43%. On February 5, the stock price increased by 5.09% to 155.87 yuan per share. The flow of funds and changes in institutional holdings may reflect market sentiment [5].

Group 1 - The core viewpoint of the article emphasizes that stabilizing market value relies on enhancing the company's core competitiveness rather than short-term stock price fluctuations [1] - The company is actively promoting research and development innovation, as well as channel optimization, to strengthen its operational foundation [1] - The company aims to reward investors with long-term development results through its ongoing initiatives [1]

Core Viewpoint - The company, Aimeike (300896), is focused on its core business and is increasing its research and development efforts to support the successful launch of new products in the future, thereby enhancing its core competitiveness [1] Group 1 - The company is continuously focusing on its main business operations [1] - The company is increasing its investment in research and development [1] - The efforts in R&D are aimed at laying a solid foundation for the successful launch of new products [1]

Core Insights - The event "2026 Advanced Aesthetics Camp" held in Hangzhou highlighted the influence of Korean natural aesthetics, with Sirifill as a key partner, introducing a new technological perspective and aesthetic inspiration focused on long-term beauty [1] Group 1: Product and Technology - Sirifill, originating from the Genoss Biotech Laboratory in Korea, focuses on the refined aesthetic needs of Asian faces, utilizing the unique LEO pure cross-linking technology for excellent extensibility and cohesiveness [3] - The product is particularly effective in achieving precise volume supplementation and smooth transitions for the softer bone structure and delicate subcutaneous tissue typical of Eastern individuals, enhancing natural contouring [3] Group 2: Clinical Application and Feedback - A physician shared that the injection experience with Sirifill is very smooth, allowing for easier "layered" injection techniques that unify bone support and aesthetic appeal, resulting in impressive immediate smoothness and naturalness post-procedure [5] - The event emphasized the importance of "light and shadow" in facial aesthetics, with Sirifill embodying this concept through its gradual and uniform metabolic process, aligning with the theme of "being friends with time" [7] Group 3: Collaboration and Future Plans - Sirifill's participation signifies not just a product offering but the introduction of a comprehensive Korean aesthetic system, aiming to integrate safe, precise, and natural injection philosophies with local aesthetic needs [11] - The successful collaboration at the aesthetics camp marks Sirifill's entry into the Chinese medical aesthetics dialogue, with plans for ongoing partnerships with domestic aesthetic institutions to enhance clinical exchanges and technical training for physicians [13]

Group 1 - The core viewpoint of the article is that Guosen Securities has given a "better than market" rating to Aimeike (300896.SZ) based on recent developments in its product pipeline and market potential [1] - Aimeike's exclusive distribution of Huons BioPharma's injectable botulinum toxin product has received regulatory approval for sale in China, including Hong Kong and Macau, filling a gap in its product line [1] - The company is expected to enhance its core competitiveness by offering comprehensive solutions through the combination of new and existing products, with ongoing research and development in weight management and submental fat products [1] Group 2 - The medical aesthetics consumption penetration rate still has significant room for improvement, indicating potential growth opportunities for the industry [1] - Aimeike is investing in self-research to develop new product lines while also pursuing mergers and acquisitions to enrich its product pipeline and expand international business [1] - The company’s performance growth is supported by these strategies, although there are potential risks related to project progress and market competition [1]

Core Viewpoint - The article discusses the recent conflicts between medical beauty company New Oxygen and its upstream suppliers due to New Oxygen's low pricing strategy, which has led to a significant drop in its stock price and supplier resistance [3][6]. Summary by Sections Supplier Conflicts - New Oxygen's low pricing strategy has intensified conflicts with suppliers, leading to several suppliers, including Faiman Bio, ceasing to supply products to New Oxygen since October 1 [3][4]. - Suppliers claim that New Oxygen's pricing disrupts the market's pricing system, resulting in a "supply cut" from multiple manufacturers [5][6]. Pricing Strategy - New Oxygen offers its own brand of "童颜针" (youthful needle) products at significantly lower prices compared to the market, with prices as low as 999 yuan for the basic version and 2999 yuan for the upgraded version [5]. - The article highlights that while major brands price their products above 10,000 yuan, New Oxygen's pricing strategy allows it to sell similar products for much lower prices, attracting a large customer base [5][6]. Business Model - New Oxygen's business model is characterized by using low prices as a customer acquisition strategy, collaborating with upstream manufacturers to eliminate middlemen and reduce costs [6][7]. - The company reportedly utilizes lower-cost OEM production methods, allowing it to maintain high profit margins despite lower retail prices [6][7]. Market Impact - The ongoing conflict between New Oxygen and its suppliers is expected to have limited long-term effects on the overall market, with the public disputes serving to clarify positions among the involved parties [8].

Core Viewpoint - The low-price strategy of the medical beauty company New Oxygen has intensified conflicts with upstream suppliers, leading to resistance from multiple vendors and a significant drop in its stock price [1][3]. Group 1: Pricing Strategy and Market Impact - New Oxygen's model involves attracting customers through low prices by collaborating with upstream manufacturers of "童颜针" (youthful needle) and eliminating intermediaries to significantly reduce product costs and achieve higher profits [1][4]. - The company's pricing for "童颜针" products is substantially lower than the market average, with some products priced at 4999 yuan and 5999 yuan, compared to official prices exceeding 10,000 yuan [3][4]. - New Oxygen's aggressive pricing strategy has disrupted the market's pricing system, prompting suppliers to cut off supplies [4]. Group 2: Supplier Relations and Compliance Issues - Suppliers, including斐缦生物 and 普丽妍, have publicly declared New Oxygen as a non-compliant partner, halting supplies and labeling its sales as potentially involving counterfeit products [1][3]. - Despite supplier claims, New Oxygen continues to sell certain products, asserting that they are traceable through official channels [3]. - The compliance of New Oxygen's products is under scrutiny, as newer domestic brands may lack the long-term safety data compared to established international brands [5]. Group 3: Business Model and Industry Context - New Oxygen's business model is seen as a survival strategy in a competitive medical beauty market, leveraging excess production capacity from smaller brands to offer low-priced products [5]. - The industry comparison to smartphone branding illustrates how lower-priced products can still maintain profitability despite significant price differences from premium brands [4][5]. - The ongoing conflict with suppliers is expected to have limited deep impacts on the overall market, serving primarily to clarify positions among the involved parties [5].